000155714 001__ 155714
000155714 005__ 20240404115649.0
000155714 0247_ $$2doi$$a10.1002/acn3.51402
000155714 0247_ $$2pmid$$apmid:34129723
000155714 0247_ $$2pmc$$apmc:PMC8283172
000155714 0247_ $$2altmetric$$aaltmetric:107698798
000155714 037__ $$aDZNE-2021-00882
000155714 041__ $$aEnglish
000155714 082__ $$a610
000155714 1001_ $$0P:(DE-HGF)0$$aBergström, Sofia$$b0
000155714 245__ $$aMulti-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease.
000155714 260__ $$aChichester [u.a.]$$bWiley$$c2021
000155714 3367_ $$2DRIVER$$aarticle
000155714 3367_ $$2DataCite$$aOutput Types/Journal article
000155714 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712138510_27005
000155714 3367_ $$2BibTeX$$aARTICLE
000155714 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155714 3367_ $$00$$2EndNote$$aJournal Article
000155714 520__ $$aDecreased amyloid beta (Aβ) 42 together with increased tau and phospho-tau in cerebrospinal fluid (CSF) is indicative of Alzheimer's disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.We utilized an antibody-based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP-regulated phosphoprotein 21 (ARPP21), growth-associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
000155714 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155714 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155714 650_2 $$2MeSH$$aAdult
000155714 650_2 $$2MeSH$$aAged
000155714 650_2 $$2MeSH$$aAged, 80 and over
000155714 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000155714 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aAquaporin 4: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aBrain: metabolism
000155714 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000155714 650_2 $$2MeSH$$aCohort Studies
000155714 650_2 $$2MeSH$$aCross-Sectional Studies
000155714 650_2 $$2MeSH$$aFemale
000155714 650_2 $$2MeSH$$aGAP-43 Protein: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aHumans
000155714 650_2 $$2MeSH$$aMale
000155714 650_2 $$2MeSH$$aMiddle Aged
000155714 650_2 $$2MeSH$$aNerve Tissue Proteins: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aPeptide Fragments: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aPhosphoproteins: cerebrospinal fluid
000155714 650_2 $$2MeSH$$aProtein Array Analysis: methods
000155714 650_2 $$2MeSH$$abeta-Synuclein: cerebrospinal fluid
000155714 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000155714 7001_ $$0P:(DE-HGF)0$$aRemnestål, Julia$$b1
000155714 7001_ $$0P:(DE-HGF)0$$aYousef, Jamil$$b2
000155714 7001_ $$0P:(DE-HGF)0$$aOlofsson, Jennie$$b3
000155714 7001_ $$0P:(DE-HGF)0$$aMarkaki, Ioanna$$b4
000155714 7001_ $$aCarvalho, Stephanie$$b5
000155714 7001_ $$0P:(DE-HGF)0$$aCorvol, Jean-Christophe$$b6
000155714 7001_ $$0P:(DE-HGF)0$$aKultima, Kim$$b7
000155714 7001_ $$aKilander, Lena$$b8
000155714 7001_ $$aLöwenmark, Malin$$b9
000155714 7001_ $$0P:(DE-HGF)0$$aIngelsson, Martin$$b10
000155714 7001_ $$0P:(DE-HGF)0$$aBlennow, Kaj$$b11
000155714 7001_ $$0P:(DE-HGF)0$$aZetterberg, Henrik$$b12
000155714 7001_ $$0P:(DE-HGF)0$$aNellgård, Bengt$$b13
000155714 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b14$$udzne
000155714 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b15$$udzne
000155714 7001_ $$0P:(DE-HGF)0$$aBosch, Beatriz$$b16
000155714 7001_ $$0P:(DE-HGF)0$$aSanchez-Valle, Raquel$$b17
000155714 7001_ $$0P:(DE-HGF)0$$aMånberg, Anna$$b18
000155714 7001_ $$0P:(DE-HGF)0$$aSvenningsson, Per$$b19
000155714 7001_ $$0P:(DE-HGF)0$$aNilsson, Peter$$b20
000155714 773__ $$0PERI:(DE-600)2740696-9$$a10.1002/acn3.51402$$gVol. 8, no. 7, p. 1456 - 1470$$n7$$p1456 - 1470$$tAnnals of Clinical and Translational Neurology$$v8$$x2328-9503$$y2021
000155714 8564_ $$uhttps://pub.dzne.de/record/155714/files/DZNE-2021-00882.pdf$$yOpenAccess
000155714 8564_ $$uhttps://pub.dzne.de/record/155714/files/DZNE-2021-00882.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155714 909CO $$ooai:pub.dzne.de:155714$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000155714 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000155714 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000008$$aExternal Institute$$b15$$kExtern
000155714 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155714 9141_ $$y2021
000155714 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN CLIN TRANSL NEUR : 2021$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:11Z
000155714 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000155714 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:11Z
000155714 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155714 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000155714 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-02
000155714 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN CLIN TRANSL NEUR : 2021$$d2022-11-09
000155714 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-02-02
000155714 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000155714 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-02
000155714 9201_ $$0I:(DE-2719)1011301$$kBiomarker$$lInterventional Trials and Biomarkers in Neurodegenerative Diseases$$x0
000155714 980__ $$ajournal
000155714 980__ $$aVDB
000155714 980__ $$aUNRESTRICTED
000155714 980__ $$aI:(DE-2719)1011301
000155714 9801_ $$aFullTexts